The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2018 | Future of aggressive lymphoma treatment: a shift towards chemo-free regimens
Speaking from the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL, Raúl Córdoba, MD, PhD, MS, of the Fundacion Jimenez Diaz University Hospital, Madrid, Spain, describes how it is likely that the treatment of lymphoma will shift towards chemotherapy-free approaches, which will be mostly based around CAR T-cell and other immunotherapies. Dr Córdoba then discusses clinical trial results that support this idea.
